Research
Distinct T cell subsets associated with responses to different neoadjuvant treatments in esophageal squamous cell carcinoma
Cell Reports Medicine · By Xin-Yun Song, Zhi-Chao Liu, Hui-Hui Hu, Yue Li, Lin Lin, Yang Yang, Hong-Xuan Li, Wen Feng, Qin Zhang, Xu-Wei Cai, Jun Liu, Wen Yu, Zhi-Gang Li & Xiao-Long Fu ·
The Brief
- Study by Song et al. compares T cell subsets in esophageal squamous cell carcinoma under two neoadjuvant treatments.
- Neoadjuvant immunochemotherapy maintains immunoresponsive CXCL13+ CD8+ T cells, per the source.
- Chemoradiotherapy reduces the CXCL13+ CD8+ T cell compartment and enriches PD-1- effector CD8+ T cells, per the source.
Why it matters
The findings link specific T cell populations to treatment response, which may help explain why patients respond differently to immunochemotherapy versus chemoradiotherapy in esophageal cancer.
Who’s affected
- oncologists and cancer researchers
- clinicians treating esophageal squamous cell carcinoma
- #esophageal cancer
- #t cells
- #immunotherapy
- #neoadjuvant therapy
- #tumor immunology
Song et al. find that neoadjuvant immunochemotherapy maintains immunoresponsive CXCL13+ CD8+ T cells, with responders showing a shift toward a less exhausted, progenitor-like phenotype, whereas chemoradiotherapy reduces this compartment and enriches PD-1- effector CD8+ T cells…
Timeline
Study published in Cell Reports Medicine
cell.com
Distinct T cell subsets associated with responses to different neoadjuvant treatments in esophageal squamous cell carcinoma